Menu Search
Equities

Tenax Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
YBO0:MUN

Tenax Therapeutics Inc

Actions
  • Price (EUR)189.76
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.4045
Data delayed at least 15 minutes, as of Jan 18 2023 07:02 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

  • Revenue in USD (TTM)0.00
  • Net income in USD-43.33m
  • Incorporated2008
  • Employees4.00
  • Location
    Tenax Therapeutics Inc101 GLEN LENNOX DRIVE, SUITE 300CHAPEL HILL 27517United StatesUSA
  • Phone+1 (919) 855-2100
  • Fax+1 (302) 655-5049
  • Websitehttp://www.tenaxthera.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.